Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 3 |
Neoplasms | 3 |
Immune System Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
CDK4 x CDK6 x CDK9 | 1 |
mTORC1 x mTORC2 | 1 |
PI3Kδ(Phosphatidylinositol 3 kinase delta) | 1 |
Target |
Mechanism PI3Kδ inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism mTORC1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK4 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date07 Aug 2023 |
Sponsor / Collaborator |
Start Date01 Jan 2023 |
Sponsor / Collaborator |
Start Date22 Nov 2022 |
Sponsor / Collaborator MEI Pharma, Inc. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Voruciclib Hydrochloride ( CDK4 x CDK6 x CDK9 ) | Diffuse Large B-Cell Lymphoma More | Phase 1 |
Zandelisib ( PI3Kδ ) | Marginal Zone B-Cell Lymphoma More | Discontinued |
ME-344 ( mTORC1 x mTORC2 ) | FGF19 positive Solid Tumors More | Discontinued |
ME-143 ( NOX ) | Solid tumor More | Discontinued |
Pracinostat Hydrochloride ( HDAC1 x HDAC2 ) | Myelodysplastic Syndromes More | Discontinued |